Abstract | BACKGROUND: EXPERIMENTAL DESIGN: RESULTS AND CONCLUSIONS: CD-expressing tumor cells (4TCD(y)) were highly sensitive to treatment by 5-fluorocytosine prodrug (P < 0.0001). 5-Fluorocytosine treatment of 4TCD(y), but not 4T1 cells, enhanced the effects of radiation in vitro (P < 0.0001). 5-Fluorocytosine prodrug treatment also increased the therapeutic potential of radiation in vivo. Mice with 4TCD(y) intrafemoral tumors showed increased effectiveness of radiation based on improved reductions in tumor size, reductions in tumorigenic osteolysis, and a decrease in skeletal fractures (P < 0.01).
|
Authors | Michael Goblirsch, Pawel Zwolak, Margaret L Ramnaraine, Weihong Pan, Christine Lynch, Parham Alaei, Denis R Clohisy |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 12
Issue 10
Pg. 3168-76
(May 15 2006)
ISSN: 1078-0432 [Print] United States |
PMID | 16707617
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antimetabolites
- Genetic Markers
- Prodrugs
- Radiation-Sensitizing Agents
- Receptor, Nerve Growth Factor
- Flucytosine
- Cytosine Deaminase
|
Topics |
- Animals
- Antimetabolites
(pharmacology)
- Bone Neoplasms
(radiotherapy, secondary)
- Carcinoma
(pathology, radiotherapy)
- Combined Modality Therapy
- Cytosine Deaminase
(biosynthesis, genetics, metabolism)
- Disease Models, Animal
- Female
- Flucytosine
(pharmacology)
- Fractures, Bone
(etiology, prevention & control)
- Genetic Markers
- Genetic Therapy
- Mammary Neoplasms, Animal
(pathology, radiotherapy)
- Mice
- Osteolysis
(etiology, prevention & control)
- Pain
(etiology, prevention & control)
- Prodrugs
- Radiation-Sensitizing Agents
(pharmacology)
- Random Allocation
- Receptor, Nerve Growth Factor
(genetics)
- Transduction, Genetic
- Treatment Outcome
|